Legal & General Group’s Vaxcyte PCVX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $4.34M | Buy |
133,562
+3,690
| +3% | +$120K | ﹤0.01% | 1617 |
|
|
2025
Q1 | $4.9M | Buy |
129,872
+6,208
| +5% | +$234K | ﹤0.01% | 1540 |
|
|
2024
Q4 | $10.1M | Buy |
123,664
+24,136
| +24% | +$1.98M | ﹤0.01% | 1159 |
|
|
2024
Q3 | $11.4M | Buy |
99,528
+3,218
| +3% | +$368K | ﹤0.01% | 1114 |
|
|
2024
Q2 | $7.27M | Buy |
96,310
+1,527
| +2% | +$115K | ﹤0.01% | 1316 |
|
|
2024
Q1 | $6.47M | Buy |
94,783
+14,780
| +18% | +$1.01M | ﹤0.01% | 1385 |
|
|
2023
Q4 | $5.02M | Buy |
80,003
+4,573
| +6% | +$287K | ﹤0.01% | 1500 |
|
|
2023
Q3 | $3.85M | Buy |
75,430
+4,851
| +7% | +$247K | ﹤0.01% | 1579 |
|
|
2023
Q2 | $3.52M | Buy |
70,579
+4,457
| +7% | +$223K | ﹤0.01% | 1646 |
|
|
2023
Q1 | $2.48M | Buy |
66,122
+39,805
| +151% | +$1.49M | ﹤0.01% | 1783 |
|
|
2022
Q4 | $1.26M | Buy |
26,317
+10,573
| +67% | +$507K | ﹤0.01% | 2074 |
|
|
2022
Q3 | $378K | Buy |
15,744
+309
| +2% | +$7.42K | ﹤0.01% | 2415 |
|
|
2022
Q2 | $337K | Buy |
15,435
+6,591
| +75% | +$144K | ﹤0.01% | 2453 |
|
|
2022
Q1 | $214K | Buy |
8,844
+727
| +9% | +$17.6K | ﹤0.01% | 2643 |
|
|
2021
Q4 | $194K | Sell |
8,117
-139
| -2% | -$3.32K | ﹤0.01% | 2736 |
|
|
2021
Q3 | $210K | Buy |
8,256
+4,124
| +100% | +$105K | ﹤0.01% | 2675 |
|
|
2021
Q2 | $93K | Buy |
4,132
+489
| +13% | +$11K | ﹤0.01% | 2765 |
|
|
2021
Q1 | $72K | Buy |
3,643
+946
| +35% | +$18.7K | ﹤0.01% | 2709 |
|
|
2020
Q4 | $71K | Buy |
2,697
+626
| +30% | +$16.5K | ﹤0.01% | 2688 |
|
|
2020
Q3 | $102K | Buy |
+2,071
| New | +$102K | ﹤0.01% | 2485 |
|